Literature DB >> 22332871

Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.

Gina Song1, Huali Wu, Keisuke Yoshino, William C Zamboni.   

Abstract

Various attempts to increase the therapeutic index of the drug while minimizing side effects have been made in drug delivery systems. Among several promising strategies, liposomes represent an advanced technology to target active molecules to the site of action. Rapid clearance of circulating liposomal drugs administered intravenously has been a critical issue because circulation time in the blood affects drug exposure at the target site. The clinical use of liposomal drugs is complicated by large intra- and interindividual variability in their pharmacokinetics (PK) and pharmacodynamics (PD). Thus, it is important to understand the factors affecting the PK/PD of the liposomal formulation of drugs and to elucidate the mechanisms underlying the variability in the PK/PD of liposomal drugs. In this review article, we describe the characteristics of liposome formulations and discuss the effects of various factors, including liposome-associated factors, host-associated factors, and treatment on the PK/PD of liposomal agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22332871     DOI: 10.3109/08982104.2012.655285

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  27 in total

1.  PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation.

Authors:  Manju Kanamala; Brian D Palmer; Hamidreza Ghandehari; William R Wilson; Zimei Wu
Journal:  Pharm Res       Date:  2018-05-31       Impact factor: 4.200

Review 2.  When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

Authors:  Stephan T Stern; Marilyn N Martinez; David M Stevens
Journal:  Drug Metab Dispos       Date:  2016-09-26       Impact factor: 3.922

3.  Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production.

Authors:  Michael A Collier; Eric M Bachelder; Kristy M Ainslie
Journal:  Pharm Res       Date:  2016-11-28       Impact factor: 4.200

4.  Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer.

Authors:  Chih-Yung Yang; Hong-Wen Liu; Ya-Ching Tsai; Ju-Yu Tseng; Shu-Ching Liang; Chin-Yau Chen; Wei-Nan Lian; Ming-Cheng Wei; Maggie Lu; Ruey-Hwa Lu; Chi-Hung Lin; Jeng-Kai Jiang
Journal:  Cancer Biol Ther       Date:  2015-10-05       Impact factor: 4.742

5.  Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location.

Authors:  Jillian L Perry; Kevin G Reuter; J Christopher Luft; Chad V Pecot; William Zamboni; Joseph M DeSimone
Journal:  Nano Lett       Date:  2017-04-11       Impact factor: 11.189

6.  Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.

Authors:  Gina Song; David B Darr; Charlene M Santos; Mark Ross; Alain Valdivia; Jamie L Jordan; Bentley R Midkiff; Stephanie Cohen; Nana Nikolaishvili-Feinberg; C Ryan Miller; Teresa K Tarrant; Arlin B Rogers; Andrew C Dudley; Charles M Perou; William C Zamboni
Journal:  Clin Cancer Res       Date:  2014-09-17       Impact factor: 12.531

7.  Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.

Authors:  Brittney R Starling; Parag Kumar; Andrew T Lucas; David Barrow; Laura Farnan; Laura Hendrix; Hugh Giovinazzo; Gina Song; Paola Gehrig; Jeannette T Bensen; William C Zamboni
Journal:  Cancer Chemother Pharmacol       Date:  2018-10-16       Impact factor: 3.333

8.  Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats.

Authors:  Daphnée Veilleux-Lemieux; Aude Castel; Denise Carrier; Francis Beaudry; Pascal Vachon
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

9.  A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.

Authors:  Yi Zhao; Daria Y Alakhova; Jong Oh Kim; Tatiana K Bronich; Alexander V Kabanov
Journal:  J Control Release       Date:  2013-03-06       Impact factor: 9.776

Review 10.  Current understanding of interactions between nanoparticles and the immune system.

Authors:  Marina A Dobrovolskaia; Michael Shurin; Anna A Shvedova
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.